Get started
Work

P-329 A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma

Year: 2023
Type: conference-abstract
DOI: 10.1016/s2152-2650(23)01947-x
Authors: Andrew Yee, Omar Nadeem, Jacalyn Rosenblatt, Adam Sperling, Giada Bianchi, Nikhil Munshi, Elizabeth O'Donnell, Andrew Branagan, David Avigan, Jessica Liegel, Cynthia Harrington, Emerentia Agyemang, Kathleen Lively, Lisette Packer, Samuel Han, Cole Minsky, Manal Riadi, Cailin McVey, Kaleigh Donnelly, Caitlin Smith, Mackenna Katzeff, Amy Goguen, Nora Horick, Paul Richardson, Noopur Raje
Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Harvard University, Dana-Farber Brigham Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4387003809
Cites:
Cited by:
Related to: 10